Progress of Neoadjuvant Immunotherapy for Non-small Cell Lung Cancer / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 524-533, 2022.
Article
in Chinese
| WPRIM
| ID: wpr-939742
ABSTRACT
Neoadjuvant immunotherapy, including neoadjuvant single- or dual-drug immunotherapy or combined immunotherapy with chemotherapy or radiotherapy, has witnessed a rapid development in non-small cell lung cancer. Clinical trials exhibited the encouraging pathological responses and certain clinical benefits in selected patients, with tolerable toxicity. Nivolumab with chemotherapy has been approved by Food and Drug Administration (FDA) as the first immunotherapy-based treatment for non-small cell lung cancer in the neoadjuvant treatment setting. There is the need for further evaluation of long-term efficacy, side effects or surgical issues for neoadjuvant immunotherapy in non-small cell lung cancer.
.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Carcinoma, Non-Small-Cell Lung
/
Neoadjuvant Therapy
/
Antineoplastic Agents, Immunological
/
Nivolumab
/
Immunotherapy
/
Lung Neoplasms
Limits:
Humans
Language:
Chinese
Journal:
Chinese Journal of Lung Cancer
Year:
2022
Type:
Article
Similar
MEDLINE
...
LILACS
LIS